Objective: Women with primary ovarian insufficiency (POI) display low androgen levels, which could contribute to mood and behavioral symptoms observed in this condition. We examined the effects of physiologic testosterone therapy added to standard estrogen/progestin therapy on quality of life, self-esteem, and mood in women with POI.
P rimary ovarian insufficiency (POI) affects approximately 1% of women before age 40 years and is accompanied by infertility, decreased quality of life, depression, and increased risks for osteoporosis and cardiovascular disease. 1<5 In addition to decreased ovarian estradiol and progesterone production, women with POI have lower circulating levels of androgens compared with women who have normal ovarian function. 6<9 Total production of testosterone in women is estimated to be approximately 300 Kg/day, with ovarian production of testosterone accounting for approximately 50% of this total daily secretion; in women with POI, there is considerable evidence suggesting that ovarian testosterone production is insufficient. Current hormone therapy strategies were developed for women experiencing natural menopause at a mean age of 50 years. However, despite the large number of studies on hormone therapy in normally postmenopausal women, less is known about the effects of menopausal hormone therapy on ovarian failure in young women. Women with POI will take estrogen therapy for decades, and the potential long-term sequelae of prolonged reduced serum testosterone levels in these women are unknown. Thus, our overall goal was to examine the effects (both beneficial and adverse) of restored normal circulating levels of testosterone on quality of life, mood, and self-esteem in young women with POI. Specifically, this study was designed to neither examine the effects of pharmacologic doses of testosterone on these behavioral measures nor specifically test the efficacy of physiologic testosterone therapy in depressive symptoms in these women. Young women with androgen deficiency may experience a variety of physical symptoms secondary to their androgen depletion, as well as psychological changes that affect their quality of life.
1 Androgen deficiency in women could contribute to depressed mood and reduced quality of life, 10, 11 and testosterone therapy has been recommended in some women with POI who present with decreased well-being, persistent fatigue, and low libido despite adequate estrogen therapy. 12 Studies have also demonstrated the beneficial effects of androgen therapy on mood and libido in hypogonadal women who had undergone surgical menopause, or who had concurrent medical or psychiatric illnesses (eg, human immunodeficiency virus and anorexia nervosa, respectively), or who had experienced reproductive aging.
13<18
A recent study also reported the beneficial effects of testosterone therapy, under placebo-controlled conditions, on quality of life in women with Turner syndrome (TS) who, like women with POI, experience ovarian insufficiency. 19 Finally, physiologic testosterone therapy has been reported to improve mood in women with anorexia nervosa. 18 Nonetheless, some studies suggest that testosterone therapy could negatively impact mood and behavior
20<22
; therefore, evaluation of its effects on these women is warranted. However, there are less data available on the effects of testosterone on quality of life and mood in young hypogonadal women with POI. As part of a 3-year placebocontrolled trial examining the effects of the addition of testosterone to combined estrogen-progestin therapy (EPT) on measures of bone density in POI, we examined the effects of the addition of the ovarian production rate of testosterone on measures of quality of life, self-esteem, and depressive symptom severity in 128 women with spontaneous 46,XX POI.
METHODS

Participant selection
Women aged between 18 and 42 years participated in this National Institute of Child Health and Human Development study at the National Institutes of Health (NIH) Clinical Center from 2000 to 2006. This study was part of a larger 3-year randomized controlled trial investigating the effects of testosterone augmentation of a combined EPT regimen on measures of bone density. 6 Participants were recruited through notices on the NIH home page or physician referral, and each woman provided a written informed consent form for participation in this Institutional Review BoardYapproved protocol. The diagnosis of POI for this study was based on a history of at least 4 months of noniatrogenic oligoamenorrhea occurring in women younger than 40 years and at least two determinations of menopausal serum follicle-stimulating hormone (FSH) levels (940 mIU/mL), as well as a normal 46,XX peripheral karyotype. Participants with baseline serum free testosterone levels above 3.1 pg/mL or sex hormone binding globulin (SHBG) levels less than 36 nmol/L were excluded from the study. Additional exclusion criteria included current smokers (92 cigarettes/d), those consuming more than two alcoholic beverages daily, those with a body mass index higher than 30 kg/m 2 or lower than 19 kg/m 2 , or those with a hirsutism score higher than 8. 23 Medical history taking, physical examination, gynecologic examination, and psychiatric evaluation were performed, after which women were offered participation in the trial of testosterone therapy in addition to standard EPT. After randomization, each woman was evaluated at 3 and 12 months, after which their participation in this component of the trial was complete. Participants with current major depression or those on antidepressant therapy were not excluded from participation. Women who met criteria for depression at admission were offered standard antidepressant therapy by either their primary treating physician or an NIH physician and then reevaluated before entering this trial. The dose or type of antidepressant was not altered in any woman during the 1-year trial (unless the woman wished to stop the medicine altogether).
Study design and procedures
This was a randomized, double-blind, placebo-controlled, parallel-design trial in which we evaluated measures of quality of life, self-esteem, and depressive symptoms for 1 year to examine the efficacy of physiologic testosterone therapy in EPT (see the Consolidated Standards of Reporting Trials [CONSORT] checklist; Supplemental Digital Content 1, http://links.lww.com/MENO/A88). This trial was part of a 3-year study that focused on bone density as the primary outcome in women with POI. After screening, all participants initiated 3 months of EPT to ensure that all women began the study on a standardized EPT regimen. While continuing EPT, all women were randomized to one of two groups: a group consisting of EPT with a placebo patch and a group consisting of EPT with a testosterone patch; EPT consisted of 100 Kg of transdermal estradiol (Watson Laboratories, Salt Lake City, UT) daily with oral medroxyprogesterone acetate (10 mg daily for 12 d of each 28-d cycle). The dose of testosterone was 150 Kg/day administered transdermally (Watson Laboratories). The NIH pharmacy generated sequentially numbered patches containing either testosterone or placebo and provided that randomization number with the study medication on the day of admission. Study participants and all raters were blinded to the intervention assignment and did not have access to laboratory results or rating scale scores from prior clinic visits.
Outcome measures
Symptom ratings and blood hormone levels were obtained at three time points as follows: at baseline before randomization, 3 months after initiation of testosterone or placebo, and 12 months after initiation of testosterone or placebo. Outcome measures for this trial were both self-administered and rater-administered, and included the 14-item Quality of Life Enjoyment and Satisfaction Questionnaire (Q-Les-Q) 24 and the 10-item Rosenberg Self-Esteem Scale 25 in which higher scores reflect better quality of life and self-esteem, respectively. We used the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID) 26 to establish the presence or absence of Axis I psychiatric illness, as well as the self-administered Center for Epidemiologic Studies Depression Scale (CES-D) 27 and the rater-administered Hamilton Rating Scale for Depression (HAM-D) 28 to assess depressive symptom severity. Blood samples for hormone assays were obtained from fasting women at 8:00 AM, separated within 1 hour, and frozen at j70-C until the time of assay.
Hormonal assays
Measurement of serum total testosterone (reference range, 14-54.3 ng/dL) was performed using radioimmunoassay after extraction chromatography (Esoterix Endocrinology, Calabassa Hills, CA). Serum free testosterone (reference range, 1.3-6.8 pg/mL) was determined with equilibrium dialysis 8 and calculated from the ratio of radioactivity outside the cell to radioactivity inside the cell multiplied by the total serum testosterone. Serum estradiol, FSH, and luteinizing hormone (LH) levels were determined at the NIH Clinical Center laboratory. Estradiol was measured by a competitive chemiluminescence immunoassay (Immulite 2000), and microparticle enzyme immunoassay (AxSYM System; Abbott Diagnostics, Abbott Park, IL) was used to measure FSH and LH. Serum SHBG was measured with an immunoradiometric assay developed at Esoterix Endocrinology. The serum hormone intra-assay and interassay coefficients of variation are as follows: total testosterone (intraassay coefficient of variation, 2.9-8.0%; interassay coefficient of variation, 8.0-15.0%), free testosterone (intra-assay coefficient of variation, 6.9%; interassay coefficient of variation, 8.9-9.4%), estradiol (both intra-assay and interassay coefficients of variation, G11.0%), FSH (intra-assay coefficient of variation, 4.9%; interassay coefficient of variation, 6.5%), LH (intra-assay coefficient of variation, 5.8%; interassay coefficient of variation, 6.4%), and SHBG (intra-assay coefficient of variation, 2.4-3.9%; interassay coefficient of variation, 7.8-10.6%).
Statistical analysis
All data were analyzed using SAS version 9.2 statistical software (SAS Institute Inc, Cary, NC). Baseline characteristics of women receiving testosterone and those receiving placebo were compared using Fisher's exact test for categorical variables and Wilcoxon rank sum tests for continuous variables. Wilcoxon rank sum tests were used to compare the symptom rating scale scores and serum hormone levels of women randomized to receive testosterone and those randomized to receive placebo. The values at each clinic visit (ie, baseline, month 3, and month 12), as well as the differences in values between baseline and 3 months and between baseline and 12 months, were included in the analyses.
In addition, we compared the numbers of women on testosterone and women on placebo who met SCID criteria for major depression, as well as the numbers of women who met criteria for either clinically significant depressive symptoms (defined as CES-D score Q16 29<31 ) or subsyndromal depression (defined as CES-D score Q8 but G16 32, 33 ), at each time point using Fisher's exact test. We also used Fisher's exact test to compare the numbers of women in each treatment group who experienced a 50% or greater improvement (ie, reduction) in their CES-D scores at 12 months compared with baseline. Results are presented as mean (SD) for interval data and as counts (percentages) for nominal and ordinal data. Because of the presence of missing data, we also performed a separate repeated-measures analysis for each of the four symptom rating scores, using SAS Institute's PROC MIXED, to compare the testosterone and placebo treatment groups at 3 and 12 months. The predictor variable of interest (treatment) and month were modeled as fixed effects. The month-treatment interaction term was not significant and was therefore dropped from the final models. We included the baseline symptom rating as a covariate and used a covariance structure of compound symmetry, with the degrees of freedom computed by the KenwardRoger method. The power analysis for this study was based on the larger 3-year study on bone density outcomes whereby, using a power level of 0.90 and an > level of 0.05, a sample size of 50 women in each group was estimated to be required to detect a difference in bone mineral density related to the addition of testosterone. All P values were two tailed, with P G 0.05 considered significant.
RESULTS
Baseline characteristics
Of the 395 women with POI who were assessed for eligibility, 128 women (mean [range] age, 31.6 y) were randomized into either testosterone treatment (n = 67) or placebo (n = 61), and 123 women completed this study ( Fig.) . There was no group difference between the ages of women randomized to receive testosterone (mean [SD], 31.1 [5.8] [3.2] ) or in the number of women with POI who were treated for a thyroid condition (n = 5 and n = 6 in the testosterone and placebo groups, respectively; P = NS for all comparisons). In addition, no differences in baseline serum free testosterone (P = 0.7) or total testosterone (P = 0.2) measures were observed between groups (Table 1) . Similarly, there were no significant differences in the numbers of women meeting criteria for either major depression or subsyndromal depression at baseline between the testosterone treatment group and the placebo group. Eight women in each arm met SCID criteria for major depression (11.9% and 13.1% in the testosterone treatment and placebo groups; P = NS), whereas 4.5% (n = 3) and 11.5% (n = 7; P = NS) of women in the testosterone and placebo groups, respectively, met criteria for current minor depression. Baseline CES-D scores did not differ between those women randomized to testosterone and those randomized to placebo (P = NS). We observed no group differences in the number of women who met baseline CES-D criteria for clinically significant depressive symptoms (ie, CES-D score Q16), with 15 (22.4%) women in the testosterone arm and 7 (11.7%) women in the placebo arm meeting this threshold value (P = 0.16); nor were group differences observed in the number of women who met criteria for subsyndromal depression (26 [38.8%] in the testosterone group and 23 [37.7%] in the placebo group). A history of major depression was diagnosed by the SCID in 33 women in both the testosterone treatment arm (49%) and the placebo arm (54.1%). Eighty-five women had no lifetime DSM-IV Axis I mood disorder diagnosis (n = 43 and n = 42 in the testosterone and placebo groups, respectively; P = NS for all comparisons). Finally, a similar number of women currently receiving antidepressant treatment were randomized FIG. Study population enrollment and outcomes. An initial sample of 395 women with POI was admitted to the National Institutes of Health Clinical Center and participated in the screening portion of the longer-term study evaluating the effects of testosterone therapy on bone health between July 2000 and February 2005. Eligibility was reported as the number of women enrolled in the larger 3-year trial. Of these, 267 met exclusion criteria and 145 met inclusion criteria and were enrolled in the larger study; of the 145 women randomized to testosterone or placebo treatment, 17 declined participation in the mood component of the study. Thus, 128 women with POI who were randomized to either testosterone or placebo treatment were enrolled in our study, with 123 women completing the study. *Of the six women who had incomplete ratings at the 12-month visit, two women in the placebo arm and one woman in the testosterone treatment arm had incomplete behavior ratings (ie, Center for Epidemiologic Studies Depression Scale, Hamilton Rating Scale for Depression, or Structured Clinical Interview for DSM-IV Axis I Disorders); the other three women (present in the testosterone treatment arm) completed the Quality of Life Enjoyment and Satisfaction Questionnaire, and one of those also completed the Structured Clinical Interview for DSM-IV Axis I Disorders). Therefore, the completed data obtained from these women were included in the analysis.
to testosterone treatment (12 [18%] ) and placebo (11 [19%] ; P = NS). Of the 128 enrolled participants, 123 completed the study (Fig.) .
Treatment trial Symptom rating scores
We found no differences in either Q-Les-Q or Rosenberg Self-Esteem Scale scores among women randomized to testosterone and placebo at baseline (P = 0.4 and P = 0.7, respectively), 3 months (P = 0.3 and P = 0.8, respectively), and 12 months (P = 0.2 and P = 0.9, respectively; Table 2 ).
Mood rating scale scores and syndromal measures of depression did not differ across treatment groups after 12 months. We observed no significant differences in either CES-D scores or the change from baseline in CES-D scores between women randomized to testosterone treatment and women randomized to placebo after 3 or 12 months of treatment (P = NS for all comparisons). Similarly, we observed no differences in the Past diagnoses and current depression were based on SCID scores using DSM-IV diagnostic criteria for Axis I mood disorders. Scale scores for the Q-Les-Q range from 0 to 100, where higher numbers reflect increasing quality of life. Rosenberg Self-Esteem Scale scores range from 10 to 40, with higher scores representing increased self-esteem. CES-D scores reflect depressive symptom severity on a scale ranging from 0 to 60, with higher scores reflecting greater symptom severity (scores Q16 are consistent with major depression). HAM-D scale scores are based on a 21-item questionnaire, with scores of 14 or higher being consistent with moderate depression (higher scores are indicative of greater symptom severity). 34 SCID values represent the number of women who met DSM-IV criteria for a current major depressive episode.
b P values were determined by Wilcoxon rank sum tests in all outcome measures, except for the SCID, which was analyzed using Fisher's exact test.
numbers of women with CES-D scores of 16 or higher at either the 3-month visit or the 12-month visit (P = 1.0 and P = 0.2, respectively) or in the numbers of women with CES-D scores of 8 or higher but lower than 16 at either the 3-month visit or the 12-month visit (P = 1.0 and P = 0.66, respectively). Finally, the number of women who experienced a 50% or greater reduction in CES-D scores after 12 months was no different in the testosterone treatment group compared with placebo-treated women (28 [50.9%] and 19 [36. 5%] in testosterone and placebo, respectively; P = 0.2).
A similar pattern was observed in the effects of testosterone and placebo treatments on HAM-D scores. No group differences in HAM-D rating scale scores were observed between testosterone treatment and placebo at baseline (P = 0.4), nor were treatment-related differences observed in either the scores at 3 months (P = 0.7) and 12 months (P = 0.1) or the change in scores at 3 months (P = 0.4) and 12 months (P = 0.8). Similarly, we observed no differences in the number of women who met SCID criteria for major depression across treatment groups at 3 months (P = 1.0) or 12 months (P = 0.5). In addition, in the sample of women who were not depressed at baseline (ie, women who met SCID criteria for depression were excluded), no differences in CES-D scores were observed between the numbers of women who were randomized to testosterone (n = 59) and the numbers of women who were randomized to placebo (n = 52) at 3 or 12 months (P = 0.8 and P = 0.6, respectively). Finally, we found no differences in measures of either Q-Les-Q or Rosenberg Self-Esteem Scale scores at 3 or 12 months (P = NS for all comparisons) among women randomized to testosterone and placebo who were not depressed at baseline (either by SCID diagnosis or by CES-D scores for syndromal symptoms of depression).
Adverse effects
No negative effects on mood were uniformly observed between groups (Table 3) . Indeed, no women in either treatment group dropped out of the study because of negative mood symptoms. Five women from the testosterone treatment arm dropped out of the study after 3 months: two reported skin irritation or rash, whereas the other three were lost to follow-up. Of those five women, four had nearly identical CES-D and HAM-D scores at baseline and 3 months, with no score higher than 9 on either measure. One woman reported a reduction in depressive symptoms in both CES-D and HAM-D scores from baseline (19 and 27, respectively) to 3 months (3 and 4, respectively) and discontinued the trial owing to the development of rash. Androgenic adverse effects were also reported by several women in the trial, but these adverse effects were infrequent and did not significantly differ between treatment groups.
Serum hormone levels
Significant differences in serum total testosterone levels were found among women with POI who were receiving testosterone treatment, compared with those receiving placebo, after 3 and 12 months (P G 0.001 for both groups at each time interval, respectively; Table 4 ). Similarly, significant differences in free testosterone levels were observed among women receiving testosterone treatment, compared with those receiving placebo, after both 3 and 12 months (P G 0.001 for both groups, respectively). In contrast, no group differences in serum measures of estradiol, FSH, LH, or SHBG were observed at baseline, 3 months, or 12 months (P = NS for all comparisons).
DISCUSSION
This is the first large-scale study to evaluate the effects of physiologic testosterone therapy with EPT on measures of quality of life and depressive symptoms in a sample of women with well-characterized POI. Testosterone therapy had neither detrimental nor beneficial effects, compared with placebo, on measures of quality of life and self-esteem and on several measures of mood. Despite significant elevations of serum testosterone levels during treatment, we did not observe significant improvements, compared with placebo, in any of the behavioral outcomes measured. A considerable number of women in both treatment groups met criteria for either subsyndromal or syndromal depression (ie, 61.2% and 50.0% in testosterone and placebo, respectively); nonetheless, only a small number of women in this study met criteria for major depression, most of whom 35 where a code of 1 represents a score from 1 to 8 (normal) and a code of 2 represents a score higher than 8 (abnormal). Only abnormal hirsutism scores are reported (one woman in the testosterone treatment group scored a 10 at 12 mo). d Acne measurement represents modified Cremoncini scale scores, 36 where a score from 0 to 1 represents less than 10 acne pustules (normal) and a score from 2 to 4 represents greater than 10 pustules (abnormal). Only the number of women who had abnormal acne scores is presented.
e Depilation frequency is reported as the number of times in the past month that hair has been removed from the lip or chin (range, 0-3). A score of 3 was reported as abnormal. f Reported adverse events at 3 months: two women withdrew from the study because of rash at the study patch site, neither of whom reported other (androgenic) adverse effects as the basis for their decision to withdraw from the study. g Equals 1.34%.
were on concurrent use of antidepressant medications. Thus, the results of this study cannot be interpreted to define the efficacy of testosterone therapy in women with POI who have major depression. Evidence of the failure of testosterone to significantly improve mood may suggest, albeit indirectly, that depressive symptoms in women with POI are androgen independent and perhaps related to other environmental or reproductive factors.
Our finding that testosterone augmentation of EPT was no more effective than EPT alone in measures of quality of life and mood is consistent with some, but not, all studies. Indeed, overall, the results of studies examining the effects of testosterone therapy, in addition to estrogen therapy, on mood and well-being are mixed. In ostensibly the same study, Sherwin and Gelfand 37,38 compared the effects of intramuscular preparations of estrogens with and without androgen augmentation on symptoms of depression and well-being in women who had undergone surgical menopause. Improvements in symptoms, relative to baseline, were observed with both estrogen alone and estrogen/androgen preparations; however, depression measures did not differ between women receiving combined estrogen/androgen and those receiving estrogens alone, whereas feelings of well-being were significantly higher in those women treated with added testosterone therapy. Mood enhancement also was reported in postmenopausal 39 and oophorectomized 40 women using oral preparations of estrogen and testosterone, respectively. As in our study, most of the women in these negative trials were recruited because they were hypogonadal but not necessarily symptomatic; therefore, baseline levels of mood and quality of life could have been too high or too low, respectively, to show a beneficial effect of testosterone treatment. Several studies have reported benefits of testosterone therapy in hypogonadal women (after oophorectomy), whose selection for entry into the trials was based on their complaints of a clinically significant loss of sexual function. 41<44 In the study by Shifren et al, 43 significant differences in measures of mood between testosterone and placebo were only observed in women taking a higher dose of transdermal testosterone (ie, 300 Kg/d) but not in those receiving a dose equivalent to that used in this trial. Thus, it is possible that, had we selected more symptomatic women with POI or used higher doses of transdermal testosterone, a more robust difference in mood measures or quality of life would have been observed in our study. Nonetheless, physiologic doses of testosterone therapy were observed to improve mood in a group of women with anorexia nervosa in whom depression rating scale scores were consistent with clinically significant depression (ie, Beck Depression Inventory score Q10) in approximately 50% of the sample. 18 Women with POI differ from women who have undergone surgical menopause in several clinical characteristics, including early age at onset of ovarian insufficiency, impact on potential fertility, and frequency of vasomotor symptoms. Thus, a better comparison group is women with TS, who also experience ovarian insufficiency from an early age. Indeed, in a prior study, we observed similar levels of anxiety, shyness, and low self-esteem in women with TS and POI, with both groups being more symptomatic than a healthy comparison group. 4 There has been one placebo-controlled trial of testosterone therapy in addition to estrogen therapy among women with TS. 19 In this study, quality-of-life measures improved with methyltestosterone 1.5 mg/day compared with placebo, as did several metabolic, cognitive, and sexual function measures. However, as with some studies in women who had undergone surgical menopause, the women with TS were taking Reference ranges for total testosterone, free testosterone, and SHBG correspond to Esoterix Endocrinology values, whereas those for estradiol, FSH, and LH correspond to the National Institutes of Health Clinical Center laboratory database. b P G 0.001 in both free testosterone and total testosterone measures at 3 and 12 months between treatment groups using Wilcoxon rank sum tests. P 9 0.05 for all other serum hormone comparisons. c FSH levels represent study participation values when women were on estrogen/progestin therapy and do not reflect the diagnostic serum FSH levels (940 IU/L on two occasions) obtained during screening (3 mo before study initiation when estrogen/progestin therapy was started).
oral estrogens and had lower baseline free testosterone levels than the women in this study (ie, mean free testosterone levels at baseline, 1.1 vs 2.2 pg/mL, respectively). The dose of testosterone used in women with TS was 1.5 mg of methyltestosterone and, therefore, could have been supraphysiologic compared with the doses that we used. Overall, our findings of a lack of efficacy of the addition of physiologic low-dose testosterone to estrogen therapy are consistent with several previous studies in hypogonadal women and do not support the routine use of testosterone to improve mood symptoms in women with POI. However, we cannot rule out the possibility that the selection of more symptomatic women or those with lower baseline testosterone levels, or the use of higher doses of testosterone, would result in a more robust pattern of the effects of testosterone on measures of mood symptoms, quality of life, and self-esteem.
A recent meta-analysis supported several reports that POI was accompanied by low testosterone levels compared with healthy young women. 9 Evidence of testosterone's beneficial effects on measures of quality of life, depressive symptoms, and well-being has provided indirect evidence that hypoandrogenism could underlie these symptoms. The results of this trial would suggest that current mood symptoms, self-esteem, and quality of life are not reflective of the androgen deficiency state present in women with POI. In a previous study, we observed a higher-than-expected prevalence of a history of major depression in women with POI, 45 suggesting that POI conveys a vulnerability to develop depressive illness. The lack of therapeutic effects of testosterone on depressive symptoms in these women with POI does not rule out the possibility that testosterone deficiency contributes to an underlying vulnerability to depressive illness. Thus, it is possible that, as with depression during natural menopause, 46 abnormalities of testosterone secretion could contribute to an increased risk for depression. Moreover, testosterone therapy's preventive effect against the risk for depression in these women remains a possibility that needs to be examined. Similarly, because estrogen has reported antidepressant effects on women with perimenopausal depression, 47, 48 it is also possible that the prestudy treatment with EPT reduced depressive symptoms sufficiently to preclude any observable additional antidepressant effects of testosterone on these women.
The findings of this study initially seem to conflict with studies that have examined the effects of testosterone and EPT 14,40<44 or testosterone alone 49, 50 on measures of sexual dysfunction. There is considerable overlap in the items measured in most quality-of-life scales and in the symptoms of both depression and decreased sexual function. Studies showing improvement in quality of life or well-being after testosterone treatment in hypogonadal women with sexual dysfunction do not necessarily reflect a concurrent improvement in mood symptoms, nor can the observed impact of testosterone on mood and well-being be generalized to hypogonadal women who do not have complaints of sexual dysfunction. Thus, comparisons are less meaningful across studies in which differing presenting symptoms are the targets of treatment. In this study, in which women were recruited for a study of bone density, quality-of-life measures could reflect a range of phenomena unrelated to depressive symptoms, and depressive symptoms would best be measured with specific depression rating scales and structured diagnostic interviews. Because neither measures of depression nor quality of life improved after EPT-plus-testosterone treatment compared with EPT, our data suggest that, in women with POI, neither measure should be an indication for testosterone treatment, in keeping with current Clinical Practice Guidelines. 51 The limitations of this study should be discussed. First, the presence of a small proportion of women who met criteria for major depression prevents an adequate evaluation of the antidepressant effects of testosterone compared with placebo. This was a clinic-based sample not selected for the presence or absence of depression, and our sample reflected the profile of symptoms encountered in a clinic-based practice more so than a sample selected for psychiatric morbidity. Although we did include women with depression, only eight women (approximately 12%) in the testosterone treatment arm met DSM criteria for major depression (compared with a 12-mo prevalence of major depression of 8.5% in the general population of women 52 ). The number of depressed women was not sufficiently large to permit the demonstration of a beneficial effect of testosterone on mood, particularly in the context of concurrent EPT, which has demonstrated antidepressant effects. 43, 44 However, to achieve 80% power in our analysis, we would need a sample size of 556 women with POI in each treatment arm for a total of 1,112 participants in the study to demonstrate antidepressant effectsVa sample size of depressed women that is prohibitively large to ethically conduct an appropriately powered study of the antidepressant efficacy of testosterone. Moreover, as stated earlier, this study was not designed to specifically evaluate the efficacy of testosterone in the treatment of depression. Nonetheless, a sample containing a larger proportion of women with depressive symptoms could allow us to make a more definitive evaluation of testosterone's mood-elevating effects. In addition, the concurrent use of antidepressant medication could have obscured testosterone's potential antidepressant effects on those depressed women on standard antidepressant medications. Finally, had we used supraphysiologic doses of testosterone, we may have identified a greater positive effect of testosterone on quality-of-life measures or mood symptoms.
CONCLUSIONS
Our data suggest that neither low self-esteem nor depressive symptoms are caused by low androgen levels in women with POI (or improve with physiologic repletion of testosterone). Moreover, reports of decreased quality of life and selfesteem or the presence of depressive symptoms could reflect a range of emotional stresses related to both the physiology of POI and the impact of the diagnosis of POI on a woman independent of an underlying gonadal steroid deficiency (both testosterone and E 2 ). There are important theoretical and practical implications to our findings. The findings beg the question, BDoes physiologic ovarian sex hormone therapy in young women with primary ovarian insufficiency improve quality of life and parameters of self-esteem and mood?[ Despite the fact that normal ovarian function provides menstruating women approximately 150 Kg of testosterone daily, testosterone therapy in these young women is not the current standard of care. 1 We have demonstrated that the 150-Kg testosterone patch does indeed achieve physiologic hormone levels in women with POI with no significant increase in adverse effects or worsening of mood compared with placebo. However, our findings suggest that testosterone therapy has a nonsignificant trend toward mood improvement in women with POI, suggesting that other mechanisms might play a more significant role in the altered mood that may accompany this disorder.
